Newsletter January 2025
Tumor Model Updates: Expanding EPO's PDX Library
Dear Colleagues,
Happy New Year! We hope your 2025 is off to a great start. Here at EPO, we are looking forward to another productive year of collaboration and innovation with our partners in industry and academia.
In driving this goal, we are thrilled to share updates on the continuing expansion of our tumor model offerings which now proudly include:
- 1000+ Highly Characterized in vivo PDX Models and in vitro PDX-Derived Cell Lines
- 400+ Pediatric PDX Models – Through collaboration with Innovative Therapies for Children with Cancer Pediatric Preclinical Proof-of-Concept Platform (ITCC-P4).
- Humanized Mouse Models – Engrafted in-house with CD34+, PBMCs, Stromal Cells, and MSCs, ensuring the Highest Quality for Immuno-Oncology Studies.
- Hematological Models – Including Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), B-Cell and T-Cell Lymphoma.
- Orthotopic / Metastatic Models – PDX, CDX, and Syngeneic Ortho / Mets Models available with Bioimaging for Luc Tagged Lines.
- CDX and Syngeneic Models – Covering All Major Tumor Types: Breast, Lung, Colon, Fibrosarcoma, Leukemia, Renal Cell, Melanoma, etc.
All of our models have been rigorously validated and characterized yielding sharable Proteomic, Transcriptomic, RNA-Seq, Molecular, and Treatment Response Data.
Highlighted below are some recent publications demonstrating the value of our PDX Models and their Characterization Data in advancing oncology drug development.
- Cancers, 2023: Development of pancreatic cancer PDX models for molecular analyses and chemosensitivity testing.
- Frontiers in Oncology, 2023: Insights into glioblastoma PDX models and temozolomide resistance.
- Molecular Cancer, 2021: Predictive molecular signatures in colorectal cancer PDX models for personalized treatments.
Advancing therapies for Treatment Resistant Cancers creates a need for tumor models that faithfully recapitulate the treatment resistance seen in clinic.
To this end, EPO offers PDX models with both Innate Resistance to SOC treatments and Induced Resistance to drugs like Doxorubicin, Vincristine, and Cetuximab.
Meet Us at the Tumor Models San Francisco Summit to Learn More!
We are excited to attend this year’s Tumor Models San Francisco Summit from January 29–31 at the Grand Hyatt San Francisco. Visit our booth to meet Turn on Javascript! and Turn on Javascript! for an expert discussion on how EPO’s tumor models can accelerate your oncology drug development.
We look forward to continuing our partnerships and supporting your breakthroughs in 2025!
Best regards,
Jens Hoffmann & Wolfgang Walther
CEO & CSO at EPO Berlin-Buch